NCT01588795 - Renal Denervation in Diabetic Nephropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Diabetic NephropathyPersistent Proteinuria With Type II Diabetes

Interventions

PROCEDURE

Percutaneous renal denervation and TMNS

Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications

DRUG

Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin

Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)

Trial Locations (1)

75015

CIC Hopital europeen george pompidou, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER